Segantii Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Segantii Capital Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$262K	–	202
2023 Q2	$262K	Hold	25,000	–	–	0.01%	147
2023 Q1	$257K	Hold	25,000	–	–	0.01%	270
2022 Q4	$254K	Hold	25,000	–	–	0.01%	347
2022 Q3	$246K	Hold	25,000	–	–	0.01%	475
2022 Q2	$249	Hold	25,000	–	–	0.01%	451
2022 Q1	$247K	Hold	25,000	–	–	0.01%	484
2021 Q4	$245K	Buy	+25,000	New	+$14.1K	0.01%	472

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Segantii Capital Management's CLDI.WS Position: Q3 2023 in Review

Segantii Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2023, closing a stake of 25,000 shares — an estimated $262K sold.

Segantii Capital Management first reported a position in CLDI.WS in Q4 2021 and held it in 7 quarters. The position peaked at $262K in Q2 2023. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2023.

Segantii Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2023 after selling out during the quarter.
Segantii Capital Management sold 25,000 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2023, an estimated $262K.
Segantii Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 7 quarters.
Segantii Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $262K in Q2 2023.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2023.

Based on Segantii Capital Management's 13F filing for Q3 2023, filed 7 Nov 2023.